Oncosuppressor proteins of fragile sites are reduced in cervical cancer

Cancer Letters

Volumn 289, Issue 1, 2010, Pages 40-45

  Giarnieri, Enrico ^a   Zanesi, Nicola ^b   Bottoni, Arianna ^b   Alderisio, Mauro ^a   Lukic, Ankica ^a   Vecchione, Aldo ^c   Ziparo, Vincenzo ^a   Croce, Carlo Maria ^b   Mancini, Rita ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b OHIO STATE UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Cervical neoplasia; Fragile sites; Immunohistochemistry; Tumor suppressors

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; TUMOR PROTEIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WW DOMAIN CONTAINING OXIDOREDUCTASE;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GRADING; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC MARKER; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU;

ACID ANHYDRIDE HYDROLASES; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMOSOME FRAGILE SITES; DOWN-REGULATION; FEMALE; HELA CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

HUMAN PAPILLOMAVIRUS;

EID: 75949090625     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.07.017     Document Type: Article

References (50)

1. Brinton L.A. Epidemiology of cervical cancer. Overview. In: Munoz N., Bosch F.X., Shah K.V., and Meheus A. (Eds). Epidemiology of Cervical Cancer and Human Papillomavirus (1992), IARC Scientific Publication No.109, Lyon, France 2-23
2. The revised Bethesda System for reporting cervical/vaginal cytological diagnoses: report of the 1991 Bethesda workshop. Acta Cytol. 1992; 36: 273-276.
3. Parker M.F., Arroyo G.F., Gerardts J., Sabichi A.L., Park R.C., and Taylor R.R. Molecular characterization of adenocarcinoma of the cervix. Gynecol. Oncol. 64 (1997) 242-251
4. Nguyen H.N., and Nordquist S.R. The Bethesda system and evaluation of abnormal pap smears. Semin. Surg. Oncol. 16 (1999) 217-221
5. McLachin C.M., Tate J.E., Zitz J.C., Sheets E.E., and Crum C.P. Human papillomavirus type 18 and intraepithelial lesions of the cervix. Am. J. Pathol. 144 (1994) 141-147
6. Paquette R.L., Lee Y.Y., Wilczynsky S.P., Karmakar A., Kizaki M., and Miller C.W. Mutations of p53 and human papillomavirus infection in cervical carcinoma. Cancer (Phila). 72 (1993) 1272-1280
7. Spriggs A.L., and Boddington M.M. Progression and regression of cervical lesions: review of smears from women followed without initial biopsy or treatment. J. Clin. Pathol. 33 (1980) 517-522
8. Brescia R.J., Jenson A.B., Lancaster W.D., and Kurman R.J. The role of human papillomaviruses in the pathogenesis and histologic classification of precancerous lesions of the cervix. Hum. Pathol. 17 (1986) 552-559
9. Aaltonen L.A., Peltomaki P., and Leach F.S. Clues to the pathogenesis of familial colorectal cancer. Science (Washington DC) 260 (1993) 812-816
10. Ohta M., Inoue H., Cotticelli M.G., Kastury K., Baffa R., Palazzo J., Siprashvili Z., Mori M., McCue P., Druck T., Croce C.M., and Huebner K. The FHIT gene, spanning the chromosome 3p14. 2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84 (1996) 587-597
11. Negrini M., Monaco C., Vorechovsky I., Ohta M., Druck T., Baffa R., Huebner K., and Croce C.M. The FHIT gene at 3p14. 2 is abnormal in breast carcinomas. Cancer Res. 56 (1996) 3173-3179
12. Sozzi G., Pastorino U., Moiraghi L., Tagliabue E., Pezzella F., Ghirelli C., Tornielli S., Sard L., Huebner K., Pierotti M.A., Croce C.M., and Pilotti S. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res. 15 (1998) 5032-5037
13. Campiglio M., Pekarsky Y., Menard S., Tagliabue E., Pilotti S., and Croce C.M. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res. 15 (1999) 3866-3869
14. Guler G., Uner A., Guler N., Han S.Y., Iliopoulos D., Hauck W.W., McCue P., and Huebner K. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 15 (2004) 1605-1614
15. Baffa R., Gomella L.G., Vecchione A., Bassi P., Mimori K., Sedor J., Calviello C.M., Gardiman M., Minimo C., Strup S.E., McCue P., Kovatich A.J., et al. Loss of FHIT expression in transitional cell carcinoma of the urinary bladder. Am. J. Pathol. 156 (2000) 419-424
16. Mori M., Mimori K., Shiraishi T., Alder H., Inoue H., Tanaka Y., Sugimachi K., Huebner K., and Croce C.M. Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res. 60 (2000) 1177-1182
17. Hao X.P., Willis J.E., Pretlow T.G., Rao J.S., MacLennan G.T., Talbot I.C., and Pretlow T.P. Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Res. 60 (2000) 18-21
18. Yoshino K., Enomoto T., Nakamura T., Nakashima R., Wada H., Saitoh J., Noda K., and Murata Y. Aberrant FHIT transcripts in squamous cell carcinoma of the uterine cervix. Int. J. Cancer 76 (1998) 176-181
19. Yoshino K., Enomoto T., Nakamura T., Sun H., Ozaki K., Nakashima R., Wada H., Saitoh J., Watanabe Y., Noda K., and Murata Y. FHIT alterations in cancerous and non-cancerous cervical epithelium. Int. J. Cancer 85 (2000) 6-13
20. Wilke C.M., Hall B.K., Hoge A., Paradee W., Smith D.I., and Glover T.W. FRA3B extends over a broad region and contains a spontaneous HPV16 integration site: direct evidence for the coincidence of viral integration sites and fragile sites. Hum. Mol. Genet. 5 (1996) 187-195
21. Birrer M.J., Hendricks D., Farley J., Sundborg M.J., Bonome T., Walts M.J., and Geradts J. Abnormal Fhit expression in malignant and premalignant lesions of the cervix. Cancer Res. 59 (1999) 5270-5274
22. Takizawa S., Nakagawa S., Nakagawa K., Yasugi T., Fujii T., Kugu K., Yano T., Yoshikawa H., and Taketani Y. Abnormal Fhit expression is an independent poor prognostic factor for cervical cancer. Br. J. Cancer 88 (2003) 1213-1216
23. Huang L.W., Chao S.L., and Chen T.J. Reduced Fhit expression in cervical carcinoma: correlation with tumor progression and poor prognosis. Gynecol. Oncol. 90 (2003) 331-337
24. Bednarek A.K., Keck-Waggoner C.L., Daniel R.L., Laflin K.J., Bergsagel P.L., Kiguchi K., Brenner A.J., and Aldaz C.M. WWOX, the FRA16D gene, behaves as a suppressor of tumor growth. Cancer Res. 61 (2001) 8068-8073
25. Paige A.J., Taylor C., Hillier S.G., Farrington S., Scott D., Porteous D.J., Smyth J.F., Gabra H., and Watson J.E. WWOX: a candidate tumor suppressor gene involved in multiple tumor types. Proc. Natl. Acad. Sci. USA 98 (2001) 11417-11422
26. Ried K., Finnis M., Hobson L., Mangelsdorf M., Dayan S., Nancarrow J.K., Woollatt E., Kremmidiotis G., Gardner A., Venter D., Baker E., and Richards R.I. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum. Mol. Genet. 9 (2000) 1651-1663
27. Chang N.S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B., and Zevotek N. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J. Biol. Chem. 276 (2001) 3361-3370
28. Iliopoulos D., Guler G., Han S.Y., Druck T., Ottey M., McCorkell K.A., and Huebner K. Roles of FHIT and WWOX fragile genes in cancer. Cancer Lett. 232 (2006) 27-36
29. Nunez M.I., Ludes-Meyers J., Abba M.C., Kil H., Abbey N.W., Page R.E., Sahin A., Klein-Szanto A.J., and Aldaz C.M. Frequent loss of WWOX expression in breast cancer: correlation with estrogen receptor status. Breast Cancer Res. Treat. 89 (2005) 99-105
30. Pluciennik E., Kusinska R., Potemski P., Kubiak R., Kordek R., and Bednarek A.K. WWOX-the FRA16D cancer gene: expression correlation with breast cancer progression and prognosis. Eur. J. Surg. Oncol. 32 (2006) 153-157
31. Gourley C., Paige A.J., Taylor K.J., Scott D., Francis N.J., Rush R., Aldaz C.M., Smyth J.F., and Gabra H. WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. Int. J. Oncol. 26 (2005) 681-689
32. Watson J.E., Doggett N.A., Albertson D.G., Andaya A., Chinnaiyan A., van Dekken H., Ginzinger D., Haqq C., James K., Kamkar S., Kowbel D., Pinkel D., et al. Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer. Oncogene 23 (2004) 3487-3494
33. Park S.W., Ludes-Meyers J., Zimonjic D.B., Durkin M.E., Popescu N.C., and Aldaz C.M. Frequent downregulation and loss of WWOX gene expression in human hepatocellular carcinoma. Br. J. Cancer 91 (2004) 753-759
34. Kuroki T., Yendamuri S., Trapasso F., Matsuyama A., Aqeilan R.I., Alder H., Rattan S., Cesari R., Nolli M.L., Williams N.N., Mori M., Kanematsu T., et al. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin. Cancer Res. 10 (2004) 2459-2465
35. Kuroki T., Trapasso F., Shiraishi T., Alder H., Mimori K., Mori M., and Croce C.M. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res. 62 (2002) 2258-2260
36. Donati V., Fontanini G., Dell'Omodarme, Prati M.C., Nuti S., Lucchi M., Mussi A., Fabbri M., Basolo F., Croce C.M., and Aqeilan R.I. WWOX expression in different histologic types and subtypes of non-small cell lung cancer. Clin. Cancer Res. 13 (2007) 884-891
37. Aqeilan R.I., Kuroki T., Pekarsky Y., Albagha O., Trapasso F., Baffa R., Huebner K., Edmonds P., and Croce C.M. Loss of WWOX expression in gastric carcinoma. Clin. Cancer Res. 10 (2004) 3053-3058
38. Muller C.Y., O' Boyle J.D., Fong K.M., Wistuba I.I., Biesterveld E., Ahmadian M., Miller D.S., Gazdar A.F., and Minna J.D. Abnormalities of fragile histidine triad genomic and complementary DNA in cervical cancer: association with human papilloma virus type. J. Natl. Cancer Inst. 90 (1998) 433-439
39. Greenspan D.L., Connolly D.C., Wu R., Lei R.Y., Vogelstein J.T., Kim Y.T., Mok J.E., Munoz N., Bosch F.X., Shah K., and Cho K.R. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors. Cancer Res. 57 (1997) 4692-4698
40. Croce C.M., Sozzi G., and Huebner K. Role of FHIT in human cancer. J. Clin. Oncol. 17 (1999) 1618-1624
41. Wistuba I.I., Montellano F.D., Milchgrub S., Virmani A.K., Behrens C., Chen H., Ahmadian M., Nowak J.A., Muller C., Minna J.D., and Gazdar A.F. Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. Cancer Res. 57 (1997) 3154-3158
42. Giarnieri E., Mancini R., Pisani T., Alderisio M., and Vecchione A. Msh2, Mlh1, Fhit, p53, Bcl-2, and Bax expression in invasive and in situ squamous cell carcinoma of the uterine cervix. Clin. Cancer Res. 6 (2000) 3600-3606
43. Fabbri M., Iliopoulos D., Trapasso F., Aqeilan R.I., Cimmino A., Zanesi N., Yendamuri S., Han S.Y., Amadori D., Huebner K., and Croce C.M. WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc. Natl. Acad. Sci. USA 102 (2005) 15611-15616
44. Aqeilan R.I., Donati V., Palamarchuk A., Trapasso F., Kaou M., Pekarsky Y., Sudol M., and Croce C.M. WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res. 65 (2005) 6764-6772
45. Gaudio E., Palamarchuk A., Palumbo T., Trapasso F., Pekarsky Y., Croce C.M., and Aqeilan R.I. Physical association with WWOX suppresses c-Jun transcriptional activity. Cancer Res. 66 (2006) 11585-11589
46. Aqeilan R.I., Palamarchuk A., Weigel R.J., Herrero J.J., Pekarsky Y., and Croce C.M. Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor. Cancer Res. 64 (2004) 8256-8261
47. Smith D.I., McAvoy S., Zhu Y., and Perez D.S. Large common fragile site genes and cancer. Semin. Cancer Biol. 17 (2007) 31-41
48. Thavathiru E., Ludes-Meyers J.H., MacLeod M.C., and Aldaz C.M. Expression of common chromosomal fragile site genes, WWOX/FRA16D and FHIT/FRA3B is downregulated by exposure to environmental carcinogens, UV, and BPDE but not by IR. Mol. Carcin. 44 (2005) 174-182
49. Sbrana I., Veroni F., Nieri M., Puliti A., and Barale R. Chromosomal fragile sites FRA3B and FRA16D show correlated expression and association with failure of apoptosis in lymphocytes from patients with thyroid cancer. Genes Chrom. Cancer 45 (2006) 429-436
50. Iliopoulos D., Guler G., Han S.Y., Johnston D., Druck T., McCorkell K.A., Palazzo J., McCue P., Baffa R., and Huebner K. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 24 (2005) 1625-1633